RxDoctor Payments Data

Thomas Anderson, DO

Family Medicine · Melbourne, FLNPI 1730161548

Payments from drug & device makers

$1,848in general payments, 2019–2025

Across 115 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$460
  • Takeda Pharmaceuticals U.S.A., Inc.$258
  • Lilly USA, LLC$169
  • Novo Nordisk$144
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$143
  • Amgen$107
  • plus $568 from 15 others

What the payments were for

  • Food & beverage$1,848100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,848 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$94,886
Medicare patients
262
Services billed
917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide60$101,808
XareltoRivaroxaban27$38,582
OzempicSemaglutide15$33,804
EliquisApixaban42$31,589
JardianceEmpagliflozin25$24,325
JanuviaSitagliptin Phosphate20$19,521
FarxigaDapagliflozin Propanediol11$15,305
LinzessLinaclotide15$11,047
TrintellixVortioxetine Hydrobromide15$10,029
Tresiba Flextouch U-100Insulin Degludec13$9,813
RestasisCyclosporine13$7,893
BrilintaTicagrelor11$6,157
Dexlansoprazole DrDexlansoprazole20$4,161
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,718
Levothyroxine Sodium193$2,454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$169$101,80860 claims
Johnson & JohnsonXarelto$20$38,58227 claims
Novo NordiskOzempic$144$33,80415 claims
PfizerEliquis$91$31,58942 claims
Boehringer IngelheimJardiance$23$24,32525 claims
AstraZenecaFarxiga, Brilinta$32$21,46122 claims
AbbVieLinzess, Restasis$460$18,94128 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$258$10,02915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →